Transforming growth factor-b (TGF-b) has dual and paradoxical functions as a tumor suppressor and promoter of tumor progression and metastasis. TGF-b-mediated growth inhibition is gradually lost during melanoma tumor progression, but there are no measurable defects at the receptor level. Furthermore, melanoma cells release high levels of TGF-b to the microenvironment, which upon activation induces matrix deposition, angiogenesis, survival, and transition to more aggressive phenotypes. The SKI and SnoN protein family associate with and repress the activity of Smad2, Smad3, and Smad4, three members of the TGF-b signaling pathway. SKI also facilitates cellcycle progression by targeting the RB pathway by at least two ways: it directly associates with RB and represses its activity when expressed at high levels, and indirectly, it represses Smad-mediated induction of p21
; SnoN
The Ski protein
The ski oncogene was discovered in its viral form, v-ski, as the transforming gene of the defective Sloan Ketering Virus (Stavnezer et al., 1981) . The human SKI protein is 91% homologous to v-ski (Nomura et al., 1989) . The chicken ski protein (c-ski) shares amino-acid sequences and biological activity with the c-myc oncogene (Stavnezer et al., 1989) . Putative structural domains found in transcription factors are also located in c-Ski, mouse Ski, and human SKI proteins. These domains include from the amino-terminus: a proline-rich area, helixloop-helix motifs, a cysteine/histidine-rich area, a region of basic amino acids, and finally a leucine zipper-like domain ( Figure 1 ). The amino-terminal residues 75-304 are sufficient for the transforming activity of c-Ski (Zheng et al., 1997a) . Efficient homodimerization of Ski, mediated by a bipartite C-terminal domain consisting of five tandem repeats (TR) and a leucine zipper (LZ), correlates with efficient DNA binding and cellular transformation (Sutrave et al., 1990; Colmenares et al., 1991; Heyman and Stavnezer, 1994; Zheng et al., 1997a, b) .
c-ski appears to be phosphorylated on serine residues, and the carboxyl-terminal region is either the site of phosphorylation or is required for phosphorylation (Sutrave et al., 1990) . However, neither the c-ski kinases, nor the consequences of the putative phosphorylations have been studied in detail. Transfected c-Ski localizes to the nucleus of interphase cells (Colmenares et al., 1989) . This leads to the notion that c-Ski might function in transcription. It is important to mention, though, that endogenous SKI in melanoma tumors can also localize to the cytoplasm (Reed et al., 2001) . In mitotic cells, endogenous or transfected SKI is diffusely expressed throughout the cytoplasm with a high intensity around the chromosomes. Such localization suggests that SKI could also participate in chromatin condensation and/or chromosome segregation. This hypothesis is based on the association of SKI with protein complexes containing histone deacetylases . Overexpression of c-Ski by retroviral vectors induces transformation, anchorage independence, and muscle differentiation in avian cells (Colmenares et al., 1991) . In turn, SKI dramatically accelerates cell-cycle progression, and increases colony size and colony formation of a human melanoma cell line with poor proliferative capacity (UCD-Mel-N) (Medrano, unpublished results). These results correlate with the ability of SKI to repress the retinoblastoma protein, a crucial regulator of the mammalian cell cycle (Tokitou et al., 1999) .
SKI has been recently reassigned to chromosome 1 p36 Kokura et al., 2001) , a common region of alterations in human cancers including melanomas (Kaghad et al., 1997) . The human SKI produces multiple forms of mRNAs, with two major species of 6.8 and 5.3 kb which are not due to alternative splicing, within the coding region. The large message is coexpressed at significantly higher levels than the small one . Ski transcripts are detected in the mouse embryo at 8.5-9.5 days postcoitum, during migration of neural crest cells including melanocytes and dorsal root ganglia (Lyons et al., 1994) . Cell lines that express SKI include neuroblastoma, carcinoma of the vulva, stomach, thyroid, lung, prostate (Nomura et al., 1989) , megakaryocyte , and melanoma (Reed et al., 2001) .
During the isolation of human SKI, a SKI-related novel gene (sno) was identified (Nomura et al., 1989) . Two sno cDNAs, SnoA and SnoN, representing alucontaining and non-alu-containing sequences, respectively, were discovered. SKI and SnoN share a large region of homology in the amino terminus, and the biological activities of these related oncogenes appear to be similar (Pearson-White and Crittenden, 1997) . SnoN induces transformation and myogenic conversion of quail embryo cells when expressed at high levels (Boyer et al., 1993) . When coexpressed in vitro, c-ski and c-SnoN preferentially form heterodimers. In vivo, c-ski and c-SnoN form heterodimers that bind the GTCTA-GAC element. Tethered c-ski : Sno heterodimers that lack TR/LZ domains are more active in cellular transformation than either their monomeric counterparts, tethered ski : ski homodimers or full-length SnoN and c-ski (Cohen et al., 1999) .
Ski has been a lasting enigma for more than a decade. However, in the last four years work from several laboratories has unraveled developmental and cellautonomous pathways regulated by Ski. This protein regulates neurulation in the mouse (Berk et al., 1997; Colmenares et al., 2001) ; overexpression of X-ski into Xenopus endodermal cells results in the formation of an ectopic neural-crest-like structure (Amaravadi et al., 1997) , and it disrupts dorsal-ventral specification of neuroectoderm and mesoderm in zebrafish (Kaufman et al., 2000) . At the cellular level, SKI represses TGF-b signaling (discussed in detail in the next sections), the retinoblastoma protein RB (Tokitou et al., 1999) , and retinoic acid receptor signaling (Dahl et al., 1998a) .
SKI is a component of the histone deacetylase complex that it is involved in transcriptional repression . SKI associates with the promyelocytic leukemia (PML) protein, and the corepressors N-CoR, mSin3, and HDAC1. Such interaction is required for transcriptional repression mediated by the tumor suppressor Mad . However, SKI directly associates to N-CoR/SMRT and mSin3, but not with HDAC ( Figure 1 ). The stoichiometry between N-CoR and SKI appears to be important for repression, as overexpression of SKI partly abrogates such function. SKI is also required for transcriptional repression mediated by MeCP2, a member of the family of methyl-CpG-binding proteins ( Figure 1 ) (Kokura et al., 2001) . Except for the mouse studies, it is important to mention, though, that the SKI activities described above were observed in vitro by overexpression of SKI and other proteins. It remains to be established how SKI alters the stoichiometry of a variety of repressor complexes when it is endogenously overexpressed. The only human tumors identified to date that overexpress SKI are malignant melanomas (Reed et al., 2001) .
Ski null mice: questions and unexplained paradoxes

Ski
À/À mice die shortly after birth and present defects in neurulation, craniofacial patterning, and skeletal development ( Perinatal lethality results from excencephaly caused by failed closure of the cranial neural tube during neurulation. Apparently, no gross defects were detected in other neural-crest derived cells. These results are consistent with a model in which Ski activities are required for the successful expansion of a subset of precursors in the neuroepithelial and skeletal muscle lineages. In agreement with these conclusions, Ski À/À melanocytes isolated from the skin of pups delivered by cesarian section at embryonic day 18.5 can be readily established in culture; indicating that Ski is not essential for melanocyte migration, proliferation, or differentiation (Medrano and Colmenares, unpublished). In turn, mice lacking Sno die at an early stage of embryogenesis, indicating that Sno is required for blastocyst formation (Shinagawa et al., 2000) . The Ski and SnoN heterozygous mice are an example of as yet unexplained paradoxes of Ski and Sno functions. Although Ski and Sno are considered to be oncogenes, when challenged with carcinogens heterozygous Sno +/À mice show increased number of lymphomas compared to wild-type mice (Shinagawa et al., 2000) ; a phenotype shared by SKI +/À animals . These results apparently contradict previous results showing that Ski is a transforming protein (Colmenares et al., 1991; Dahl et al., 1998a) . However, the transforming activities of Ski and Sno might be restricted to lineages that express basal levels of these proteins including skeletal muscle and neural crest.
c-Ski is a potent repressor of TGF-b signaling
Transforming growth factor b (TGF-b) is an ubiquitous cytokine with paradoxical functions in many tissues. This topic has been extensively reviewed (Massague and Chen, 2000; Attisano et al., 2001; Derynck et al., 2001; Moustakas et al., 2001; Piek and Roberts, 2001; Rooke and Crosier, 2001; Wong and Lai, 2001; ten Dijke et al., 2002; Verrecchia and Mauviel, 2002) , therefore, I will only highlight some important findings and focus on SKI overexpression, and its consequences for TGF-b signaling, and melanoma tumor progression.
TGF-b functions as a negative growth regulator for epithelial cells from diverse tissues, but it is also a potent growth promoter for mesenchymal, smooth muscle cells, and chondrocytes. Tissue activities regulated by TGF-b include early development, cell-cycle control, differentiation, extracellular matrix deposition and remodeling, angiogenesis, chemotaxis, and induction of apoptosis (reviewed by Schuster and Krieglstein, 2002) . Carcinomas often secrete excess TGF-b and respond to it by enhanced invasion and metastasis (reviewed by Akhurst and .
Melanocytes are exquisitely sensitive to exogenous TGF-b inhibition (Rodeck et al., 1994) , but melanoma cells show various degrees of resistance (Krasagakis et al., 1999) . Melanoma cells also secrete substantial amounts of TGF-b (Krasagakis et al., 1999) , which correlates with the depth of invasion. Such an event has been proposed to be critical for the development of deep invasion and metastases in malignant melanoma (Reed et al., 1994) .
TGF-b signals are transduced by membrane serine/ threonine kinase 'type I' and 'type II' receptors (TbRI and TbRII). Signaling by TGF-b receptors is mediated by the Smads, a family of structurally related proteins. Ligand-mediated receptor activation results in carboxyterminal phosphorylation of Smad2 and Smad3, formation of heterotrimeric complexes with the common partner Smad4, nuclear translocation, and transcriptional activation of TGF-b target genes (reviewed by Piek et al., 1999; Massague and Chen, 2000; Derynck et al., 2001) .
In 1998, the Stavnezer lab using an in vitro binding assay demonstrated that c-ski, in association with unknown proteins, binds to the DNA consensus sequence GTCTAGAC (Nicol and Stavnezer et al., 1998) . This group also found that c-ski represses transcription either through upstream copies of this element or when brought to the promoter by a heterologous DNA-binding domain (Nicol and Stavnezer, 1998). The GTCTAGAC sequence, which is bound to c-ski-containing proteins was subsequently identified as a Smad-binding element (SBE) containing the four base pairs (5 0 AGAC-3 0 or its reverse complement 5 0 AGAC-3') that are directly bound by Smad3 and Smad4 proteins (Zawel et al., 1998) . Shortly after, several groups including ours demonstrated, through a variety of approaches that included affinity chromatography, GST pull-downs, and yeast two-hybrid screening (Akiyoshi et al., 1999; Luo et al., 1999; Sun et al., 1999a; Xu et al., 2000) , that Ski associates with a multi-Smad complex (Figure 1 ) that specifically binds the SBE. SKI binds the MH2 domains of Smad2 and Smad3, which are virtually identical (Figure 2) . Binding of Ski to Smad2/ Smad3 causes dissociation of the histone acetyltransferase p300 from the Smad2/3 complex and promotes association with mSin3A and histone deacetylases (Akiyoshi et al., 1999) . HDAC-containing complexes are known to repress transcription by deacetylation of histone residues, which in turn favor histone methylation and transcriptional silencing (reviewed by Rountree et al., 2001; Baylin et al., 2001 Repression of TGF-b signaling EE Medrano
SKI overexpression, localization, and function during melanoma tumor progression
Mammalian and avian melanocytes are targeted by the transforming activity of Ski. Early studies showed that v-ski induces transformation of pigmented primary quail melanocytes (Barkas, 1986) . During mouse development, Ski is expressed at relatively high levels in neural crest-derived cells (Lyons et al., 1994) , and SKI transcripts are expressed at high levels in human melanoma cell lines compared to normal melanocytes (Fumagalli et al., 1993) . Overexpression of SKI in melanomas results from yet to be defined transcriptional and/or post-transcriptional events, as Southern blot analysis did not find alterations in restriction enzyme patterns or increase in gene dosage (Fumagalli et al., 1993) . Recently, we demonstrated that SKI is overexpressed in vivo in all melanomas studied (n ¼ 44) (Reed et al., 2001) . In preinvasive melanomas in situ, SKI was observed predominantly in the nucleus of intraepidermal melanoma cells. However, most of the primary invasive melanomas demonstrated both nuclear and cytoplasmic localization of SKI, though nuclear labeling was greater in the intraepidermal melanoma cells. In melanoma metastasis, SKI localizes to both the nuclear and cytoplasmic compartments, or predominantly to the cytoplasmic compartment. Association of cytoplasmic SKI with Smad3 apparently prevents Smad3 nuclear translocation in response to TGF-b. Thus, the biological consequence of SKI/Smad3 interaction in the cytoplasm appears to be similar to NLS mutations in Smad3, as this mutant remains in the cytoplasm and functions as dominant-negative inhibitor of TGF-b signaling (Xiao et al., 2000) .
SKI represses induction of p21
Waf-1 by TGF-b
The Smad proteins regulate transcription of the cyclindependent kinase inhibitor p21 Waf-1 (Pardali et al., 2000) , which together with p15
INK4b (Feng et al., 2002) , mediate the antiproliferative and tumor suppressor activity of TGF-b. Increased p21
Waf-1 protein levels appear to be essential for TGF-b-mediated inhibition of the cyclindependent kinase CDK2 (reviewed by Moustakas et al., 2002) . The p21
Waf-1 promoter contains a proximal Sp1-binding site that confers Smad cooperativity and a distal SBE (Sobballe and Herlyn, 1994) . High levels of SKI prevent p21
Waf-1 induction through a Smad-dependent mechanism that involves transcriptional repression (Reed et al., 2001) . Thus, elevated expression of SKI facilitates cell-cycle progression by targeting the RB pathway in at least two ways; high levels can directly repress RB activity, and indirectly, increase CDK2 activity by repressing TGF-b-mediated induction of p21
Waf-1 . Importantly, such activities are reciprocal to p16
INK4a loss, an event associated with mouse and human melanoma formation and progression (reviewed by Tietze and Chin, 2000; Bardeesy et al., 2001; Yang et al., 2001 ).
In addition to SP-1, the Smad proteins functionally cooperate with a diverse number of transcription factors in response to TGF-b. For example, the heteromeric complex of Smad3 and Smad4 synergizes with c-Jun/cFos at the AP-1 binding site of the collagenase I promoter to induce transcriptional activation in response to TGF-b (Qing et al., 2000) . Cooperation between SP-1 and Smads is also repressed by SKI .
Downregulation of SKI restores TGF-b-mediated growth inhibition in human melanomas
Loss of TGF-b sensitivity is frequently observed in tumors derived from cells that are otherwise sensitive to growth inhibition by this protein, and the extent of TGF-b resistance often correlates with metastatic progression (Stone et al., 1997) . Although melanoma cells are highly resistant to the inhibitory activity of TGF-b, there are no measurable defects at the receptor level (Nishizuka, 1986; Holbrook and Fornace, 1991) . However, downregulation of SKI protein levels by antisense SKI vectors restores TGF-b-mediated growth inhibition in melanomas (Reed et al., 2001) . Therefore, elevated expression of SKI is necessary and sufficient for curtailing the inhibitory activity of TGF-b. Thus, deregulated expression of SKI represents a significant event in the progression of melanomas in vivo. Together, these results suggest that manipulation of SKI levels could be a prospective melanoma therapy.
Secreted TGF-b1 increases matrix remodeling and melanoma survival
Increased expression and activation of TGF-b1 by tumor cells stimulates extracellular matrix deposition and chemoattraction of fibroblasts, promoting tumor growth and angiogenesis (Roberts et al., 1986; Zheng et al., 1997a; Derynck et al., 2001) . TGF-b1 expression by melanoma cells can modify the surrounding stroma with increased production and deposition of extracellular matrix proteins, which favor increased metastatic spread and survival (Berking et al., 2001) .
TGF-b1 can also induce transdifferentiation of tumors from epithelial or melanocytic origin to highly malignant fibroblastoid tumors characterized by spindle-shaped cells (reviewed by Janji et al., 1999; Derynck et al., 2001) . By simultaneously repressing TGF-b-mediated growth inhibition and releasing high levels of this cytokine to the microenvironment, melanomas have developed a highly efficient, cell-autonomous pathway that stimulates proliferation, invasion, and survival (Figure 3 ). For that, the Smads meet their repressor SKI.
Perspectives and future directions
These are exciting times for SKI and Sno fans. We have learned of numerous activities regulated by these proteins, and yet, numerous unanswered questions remain. For example, what signals upregulate SKI transcription in melanomas (Fumagalli et al., 1993) . Is such an event necessary and sufficient for melanoma tumor progression as the pattern of SKI protein expression appears to indicate (Reed et al., 2001) ? Is SKI protein stability also altered? The anaphasepromoting complex is a ubiquitin ligase required for the destruction of SnoN, a pathway regulated by TGF-b (Sun et al., 1999b; Bonni et al., 2001; Stroschein et al., 2001; Wan et al., 2001) . Considering the homology with SnoN, it is likely that SKI levels are also similarly regulated. However, once again, most of these studies had used transfected proteins, therefore, we know very little on how SKI stability is regulated in melanomas. High levels of SKI displayed by all cells within a melanoma tissue section suggest that SKI might be more stable or differentially regulated in these tumors. Furthermore, cytoplasmic and nuclear SKI might display different half-lives if they localize to different protein complexes. Initial experiments in synchronized human melanoma cell lines indicate that although endogenous SKI levels consistently peak at mitosis, G1 cells of different lines show variable amounts of this protein (Medrano, unpublished results). Additional studies should determine whether such variability depends on the distribution of SKI between the cytoplasmic and nuclear compartments.
TGF-b and related factors induce apoptosis in a variety of tissues. However, melanoma tumors are notoriously resistant to apoptosis mediated by diverse insults (reviewed by Serrone and Hersey, 1999) . The death-associated protein kinase (DAP-kinase) is a calcium/calmodulin-regulated serine/threonine kinase that localizes to the cytoskeleton, participates in several apoptotic processes (reviewed by Kogel et al., 2001) and is a tumor suppressor (Kissil and Levy-Strumpf and Kimchi, 1998; Raveh and Kimchi, 2001) . Is SKI involved in the resistance to apoptosis of melanoma cells? Probably yes, as expression of the DAP-kinase is transcriptionally induced by TGF-b through canonical SBE elements in its promoter (Jang et al., 2001) .
We also know little regarding protein complex formation and activity between endogenous SKI and members of its own family such as SnoN, and with proteins that might interfere with its activity such as the SKI-interacting protein Skip (Dahl et al., 1998b) . Skip is particularly interesting as its overexpression partially overcomes Ski/Sno-dependent repression. However, Ski/Sno overexpression attenuates Skip augmentation of TGF-b-dependent transcription (Leong et al., 2001) . Considering both, resistant to TGF-b and SKI overexpression, we predict that SKI counteracts Skip activity in malignant melanoma tumors.
Another intriguing SKI partner is PML. This protein interacts with RB, and is involved in the induction of growth arrest and senescence induced by oncogenic RAS (reviewed by Salomoni and Pandolfi, 2002) . Could high levels of SKI prevent PML and p53 induction by RAS and overcome senescence?
Finally, in addition to repression, c-ski can activate transcription from some tissue-specific and viral enhancers and promoters (Engert et al., 1995; Ishikawa et al., 1997; Kelder et al., 1997) . Therefore, c-Ski can act as activator or repressor of transcription depending on protein-protein interactions dictated by the promoter and physiological context. What we presently know about SKI in melanomas is sufficient to catalogue it as an oncogene. Unraveling additional SKI functions through global approaches including microarrays and proteomics should help determine whether this protein is within the 'gut apparatus' that drives melanocyte transformation and/or tumor progression. 
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